I see ONCS delivery system eventually making it's way to dermatologists around the world.
Like other device/delivery companies, ONCS will simply facilitate training and education clinics. The procedure is non invasive and the low dose agent will require minimal malpractice insurance.
Most importantly, this simplicity and should receive FDA approval based on Phase 2 success.
Like Starbucks, ONCS will be on every corner.
Funny comparison. But I agree, it looks like ONCS here near .25 is a good buy.
Actually, I'm serious about the widespread distribution as this is a huge market and the procedure will eventually be no more involved than laser fugal treatment.
Or Pete's or Seattle's Best ...